Bacillus Calmette-Guérin Suppresses Asthmatic Responses via CD4⁺CD25⁺ Regulatory T Cells and Dendritic Cells

Young-Joon Kim,¹ Ha-Jung Kim,¹ Mi-Jin Kang,¹ Ho-Sung Yu,¹ Ju-Hee Seo,² Hyung-Young Kim,² Seoung-Ju Park,² Yong-Chul Lee,³* Soo-Jong Hong¹*

¹Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea
²Department of Pediatrics, Childhood Asthma Atopy Center, Research Center for Standardization of Allergic Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
³Department of Internal Medicine, Research Center for Pulmonary Disorders, Chonbuk National University Medical School, Jeonju, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: Bacillus Calmette-Guérin (BCG) is known to suppress the asthmatic responses in a murine model of asthma and to induce dendritic cells (DCs) maturation. Mature DCs play a crucial role in the differentiation of regulatory T cells (Tregs), which are known to regulate allergic inflammatory responses. To investigate whether BCG regulates Tregs in a DCs-mediated manner, we analyzed in a murine model of asthma. Methods: BALB/c mice were injected intraperitoneally with BCG or intravenously with BCG-stimulated DCs and then sensitized and challenged with ovalbumin (OVA). Mice were analysed for bronchial hyperresponsiveness (BHR), the influx of inflammatory cells in the bronchoalveolar lavage (BAL) fluid, and histopathological changes in the lung. To identify the mechanisms, IgE, IgG₁, and IgG₂₅ in the serum were analysed and the CD25⁺ Tregs in the mice were depleted with anti-CD25 monoclonal antibody (mAb). Results: BCG and the transfer of BCG-stimulated DCs both suppressed all aspects of the asthmatic responses, namely, BHR, the production of total IgE and OVA-specific IgE and IgGs, and pulmonary eosinophilic inflammation. Anti-CD25 Ab treatment reversed these effects. Conclusions: BCG can attenuate the allergic inflammation in a mouse model of asthma by a Tregs-related mechanism that is mediated by DCs.

Key Words: BCG; dendritic cells; T-lymphocytes, regulatory; asthma; allergic inflammation; mouse

INTRODUCTION

Asthma is a chronic inflammatory disease that is characterized by infiltration of inflammatory cells such as eosinophils, airway hypersensitivity, and airflow obstruction. Th2 cells play a particularly crucial role in the development of asthma by secreting interleukin (IL)-4, IL-5, and IL-13: IL-4 causes naïve T cells to differentiate into Th2 cells while IL-5 induces eosinophil infiltration. The hygiene hypothesis proposes that westernized culture and its associated improvements in sanitation cause the microbial exposure of the population to be reduced. This decreases Th1 immune responses that are induced, the lack of which causes the immune system to become dominated by Th2 immune responses. It has been suggested that this skewing of the immune system has caused the incidence of allergic diseases such as asthma to rise rapidly in the last few decades. However, recent studies suggest that the incidence of Th1-related diseases such as type 1 diabetes mellitus and multiple sclerosis is also increasing along with Th2-related diseases such as asthma. This indicates that other mechanisms apart from Th1/Th2 immune responses participate in the modulation of allergic inflammatory responses. One of these mechanisms may involve regulatory T cells (Tregs): several studies report that Tregs regulate immune system by suppression of the Th1/Th2 responses. Tregs, which are widely considered to be crucial suppressor T cells, act by releasing the immunosuppressive cytokines IL-10 and transform-
ing growth factor (TGF-β) and by cell-cell contact mechanism that is mediated cytotoxic lymphocyte associated antigen-4 (CTLA-4) expressed by CD4+CD25+ Tregs, which interacts with CD80 and/or CD86 on the surface of antigen-presenting cells (APCs).  

Bacillus Calmette-Guérin (BCG) is a mycobacterial vaccine organism that is used to prevent tuberculosis. It is known to modulate allergic inflammatory responses.  

The aim of the present study was to investigate the mechanism by which BCG vaccination inhibits the inflammatory responses of this mouse model; to do so, the roles of immature DCs and Tregs were analysed.

**MATERIALS AND METHODS**

**Animals**

Female BALB/c mice were purchased from Orient Bio (Seongnam, Korea) and cared for and used in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at Asan Medical Center and Ulsan University College of Medicine. The mice were housed in specific pathogen-free facility.

**Antigen sensitization and challenge**

The mice (6 weeks of age, 5 mice/group) were sensitized by 2 intraperitoneal injections with 10 µg ovalbumin (OVA; chicken egg albumin grade V, Sigma Chemical Co., St. Louis, USA) dissolved in 100 µL of phosphate-buffered saline (PBS) adsorbed to an equal volume of alum solution (Alumimag, Pierce, IL, USA) on days 0 and 7. On days 14-16, all mice were challenged daily for 30 minutes via an ultrasonic sprayer (Nescoconic UN-511, Alfresa, Osaka, Japan) with aerosolized 1% OVA (50 µg in 50 µL saline). The mice were divided into 5 groups of 5 mice each.

**BCG vaccination**

Freeze-dried living BCG vaccine was obtained from Japan BCG laboratory (Tokyo, Japan). The mice were injected intraperitoneally with BCG Tokyo 172 strain 5 days before the first sensitization (day -5) at a dose of $1 \times 10^6$ CFU/200 µL.

**DCs preparation, BCG treatment, and injection into mice**

BMDCs were generated from BALB/c (6-8-weeks-old). Briefly, bone marrow cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, antibiotic-antimycotic, and 10 ng/mL recombinant murine Granulocyte-macrophage colony-stimulating factor (GM-CSF) (R&D systems, Minneapolis, MN, USA). The culture media were replaced with fresh media containing GM-CSF on days 3 and 6. On day 6, BMDCs were collected and stained for CD11c. then, the CD11c+ cells were sorted by using autoMACS (Miltenyi Biotec) and prepared at $1 \times 10^6$ cells/10 mL, and stimulated with BCG ($1 \times 10^7$ CFU) for 48 hours *in vitro*. The mice were injected intravenously with BCG-stimulated DCs or non-stimulated DCs ($1 \times 10^6$/200 µL) 5 days before the first sensitization (day -5).

**In vivo treatment with anti-CD25 monoclonal antibody**

The administration of anti-CD25 Abs is a commonly used method to deplete Tregs *in vivo*. To investigate the mechanism by which Bregs participate in the allergy-suppressive effects of vaccination with BCG or BCG-stimulated DCs, the OVA-sensitized mice were injected intraperitoneally with 250 µg of anti-CD25 monoclonal antibody (mAb) (clone PC61, eBioscience, San Diego, USA) 1 day before the final challenge with 1% OVA.

**Measurement of bronchial hyperresponsiveness (BHR)**

Twenty-four hours after the final OVA challenge, BHR was measured in conscious unrestrained mice by using a barometric whole-body plethysmograph (one chamber plethysmography, All Medicus, Anyang, Korea), as described previously. Briefly, after inhalation of saline and each concentration of methacholine (MeCh), enhanced pause (Penh) was measured at 10-second intervals for 3 minutes, averaged, and expressed as absolute values.
Bronchoalveolar lavage (BAL) and determination of the cellular composition of the BAL fluid

After measurement of BHR, mice were anaesthetized. BAL was performed as described previously. Briefly, the trachea was immediately exposed after anesthesia. Then, BAL was performed through a catheter inserted into the exposed trachea following instillation of normal saline (2 mL) at 37°C. The BAL fluid was centrifuged at 2,000 rpm for 5 min at 4°C. After discarding the supernatant, the pellet was resuspended in 100 µL PBS. Total BAL cell counts were performed using a haemacytometer. To count the different BAL fluid cells, cytospin slides were prepared, stained with Wright stain, and the different cell types were identified on the basis of their standard morphology under a light microscope. Five sections per slide were evaluated.

Quantitation of the serum levels of immunoglobulins

Serum was collected upon sacrifice 24 hours after last 1% OVA challenge and the serum immunoglobulins were quantified by sandwich ELISA as described previously. Briefly, serum was separated from the blood clot by centrifugation at 2,500 rpm for 10 minutes at 4°C. Absorbance of Total IgE, OVA-specific IgE, IgG, and IgG₈, was measured using ELISA reader. The optical density was measured at 450 nm.

Histopathological analysis of the lungs

To histologically evaluate the lung tissues, lung samples were prepared as described previously. Inflammation was scored by 2 independent blinded investigators. The degree of peribronchial and perivascular inflammation was evaluated on a subjective scale of 0–3 as described elsewhere. Briefly, a value of 0 meant that no inflammation was detectable, a value of 1, occasional cuffing with inflammatory cells, a value of 2, most bronchi or vessels were surrounded by thin layer (1 to 5 cells thick) of inflammatory cells, and a value of 3, most bronchi or vessels were surrounded by a thick layer (more than 5 cells thick) of inflammatory cells. The cellular infiltration in 5 randomly selected fields was assessed under a Zeiss Axiophot microscope (Carl Zeiss Inc., Thornwood, USA) at 100 × .

Statistical analysis

The each group were compared by using Mann-Whitney test. The data were expressed as means ± standard deviation (SD). All statistical analyses were performed by using SPSS 18.0 for Windows (SPSS Inc., Chicago, IL, USA). A P value that was less than 0.05 was considered significant.

RESULTS

Transfer of BCG-stimulated DCs inhibits BHR and airway inflammatory cells

The MeCh-BHR in response to aerosolized MeCh was measured and the cells in the BAL fluid were identified and counted. Mean Penh value at maximum MeCh dose of the BCG-stimulated DCs mice was half those of mice, which had only been sensitized and challenged with OVA (OVA mice) (P<0.05, Fig. 1A). By contrast, the mean Penh values at maximum MeCh dose of the mice who had received non-stimulated DCs before OVA sensitization and challenge were equivalent to those of the OVA mice. In terms of the BAL fluid analyses, the mice receiving the BCG-stimulated DCs had significantly fewer infiltrating cells overall than the OVA mice (P<0.01, Fig. 1B), whereas the mice receiving non-stimulated DCs were similar to the OVA mice. With respect to specific cell types in the BAL fluid, the mice receiving the BCG-stimulated DCs had significantly fewer eosinophils than the OVA mice and the mice receiving non-stimulated DCs (P<0.01, Fig. 1B).

Transfer of BCG-stimulated DCs suppresses the inflammation of lung

Histological analysis of the lungs of the mice described above revealed that the recruitment to the lungs of peribronchial and perivascular inflammatory cells was low in mice who had received the BCG-stimulated DCs when compared to the OVA mice (Fig. 1C). In contrast, the recruitment of the mice that received the non-stimulated DCs was equivalent to that of the OVA mice (Fig. 1C).

To quantify the infiltration of inflammatory cells, peribronchial and perivascular histopathological inflammation scores were determined. Compared to the OVA mice, the inflammation score was low in the mice that had received BCG-stimulated DCs (P<0.01, Fig. 1D). By contrast, the scores of the mice that had received the non-stimulated DCs were similar to those of the OVA mice (Fig. 1D).

Transfer of BCG-stimulated DCs reduces the systemic immune response to OVA

The levels of total IgE, OVA-specific IgE, OVA-specific IgG, and OVA-specific IgG₈, in the sera of each group were measured. The OVA mice had elevated levels of total IgE and OVA-specific IgE. Both measures were significantly lower in the mice that received the BCG-stimulated DCs but not in the mice that received the non-stimulated DCs (P<0.05, P<0.01, respectively, Fig. 2). Compared to the OVA mice, the mice that received the BCG-stimulated DCs also tended to have lower OVA-specific IgG₈, levels and their OVA-specific IgG levels were significantly lower (P<0.05, Fig. 2). By contrast, the OVA-specific IgG, and OVA-specific IgG₈, levels of the mice that received the non-stimulated DCs were similar to those of the OVA mice (Fig. 2).

Anti-CD25 mAb treatment prior to OVA challenge can abrogate the effect of BCG-stimulated DCs transfer

BHR analysis revealed that the mean Penh values at maximum MeCh dose of the CD25-depleted mice were significantly higher than those of the BCG-DCs-injected mice (P<0.05, Fig 3A).
BAL fluid analysis revealed that the anti-CD25 mAb treatment also significantly increase the total cell numbers and eosinophils relative to the mice that treated the BCG-stimulated DCs (P<0.01, respectively, Fig. 3B).

There was significantly more recruitment of inflammatory cells to the lungs in the anti-CD25 mAb treated mice than in the BCG-stimulated DCs-treated mice (P<0.01, Fig. 3C and D).

**DISCUSSION**

Many studies in human and experimental work in animals showed that BCG can modulate the allergic inflammatory responses. However, the mechanism(s) by which this occurs remained unclear. In the present study, we asked whether this mechanism is associated with Tregs that are stimulated by BCG-stimulated DCs.

The present study shows that BCG vaccination and the transfer of BCG-stimulated DCs both inhibited asthmatic responses, including BHR, serum IgE production, and the numbers of inflammatory cells in the BAL fluid and lungs. In addition, treatment with anti-CD25 mAb prior to challenge abrogated these effects. These findings suggest that BCG inhibits allergic inflammatory responses by inducing Tregs, which is mediated by DCs.

The first of these experiments involved injecting mice with BCG-stimulated DCs, as this would reveal whether the inhibitory effect of BCG is associated with DCs. Indeed, compared to the OVA mice and the mice that received non-stimulated DCs, the transfer of BCG-stimulated DCs significantly suppressed the asthmatic responses, including BHR, the numbers of inflammatory cells in the BAL fluid, and the pulmonary inflammation in the lung tissue. This effect of BCG has also been observed by other studies. These results suggest that the BCG-induced maturation of DCs plays an important role in regulating allergic immune responses.

Our second experiment involved the administration of anti-CD25 mAb to determine whether the inhibitory effect of the BCG-stimulated DCs is associated with Tregs. Cell-surface CD25 is a well-known marker for Tregs. Tregs depletion by anti-CD25 mAb treatment indeed enhanced BHR and measures of airway inflammation, namely the total cell and eosinophil...
counts in the BAL fluid and the infiltration of inflammatory cells in the lung. Thus, it appears that the asthma-inhibiting effects of BCG are associated with Tregs. These observations are consistent with those of other studies that have used mouse models. For example, BCG-primed DCs were shown to enhance the expression of Foxp3 Tregs, IL-10, and inducible co-stimulator. However, interestingly, BCG-primed DCs have also been shown to upregulate Th1-associated neutrophilic inflammation; this was more effective when the Pasteur strain was used instead of the Copenhagen strain. In the present study, the Tokyo strain of BCG was used and neutrophil increases were not observed. Thus, this difference may be related to the type of BCG strain that is used. Supporting this is a study that found considerable differences in the immunogenicity of various BCG strains, namely their ability to modulate T-cell proliferation and cytokine production.

This study demonstrated that matured DCs by BCG in vitro could suppress allergic inflammation in mouse model of asthma with adoptive transfer. In light of these, our study provides a new perspective of the mechanisms by which the allergic inflammation in a mouse model of asthma can be modulated.

Further studies are needed to refine several aspects of this study. CD25 may not be sufficient to explain the mechanism of Tregs. And we did not investigate the expression of Tregs in the airway or thymus or regional lymph node and the functional cytokine production. However, BCG treatment is likely to elevate Foxp3 Tregs which is a master transcription factor of Tregs in vivo and in vitro. In addition, recent study has reported that DCs stimulated by BCG release IL-10 and induce differentiation of naïve T cells into Tregs.

BCG is also recognized as a strong Th1 immune response inducer. A study has reported that the interaction between BCG and toll-like receptor (TLR) 2 on DCs may affect the differentiation of naïve T cell mainly to Th1-like cells with the help of IL-10, IL-12, and so forth. In addition, recently, some studies have reported that IFN-γ is essential to suppress allergic responses. It would be worth to perform the study of BCG-DCs on damping allergic inflammation in IFN-γ- or TLR2-deficient mice.

In summary, the present study showed that BCG treatment inhibited the allergic responses of a mouse model of asthma; the study with BCG-stimulated DCs was consistent with these observations. In addition, anti-CD25 mAb treatment reversed the effects of BCG/BCG-DCs. These results suggest that the inhibitory effect of BCG in our mouse model of asthma is mediated by DCs, which induce Tregs.
**ACKNOWLEDGMENTS**

All authors declare there are no conflicts of interest. This study was supported by a grant from the Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084144).

**REFERENCES**

1. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992;146:109-15.
2. Lee SH, Park JS, Park CS. The search for genetic variants and epigenetics related to asthma. Allergy Asthma Immunol Res 2011;3:236-44.
3. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson C, Montovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989;19:701-5.
4. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259-60.
5. Riedler J, Braun-Fahrländer C, Eder W, Schreuer M, Maisch S, Carr D, Schierl R, Nowak D, von Mutius E; ALEX Study Team. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;358:1129-33.
6. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrländer C, Heederik D, Piarroux R, von Mutius E; GABRIELA Transregio 22 Study Group. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364:701-9.
7. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006;355:2226-35.
8. Hong SJ, Ahn KM, Lee SY, Kim KE. The prevalences of asthma and allergic diseases in Korean children. Korean J Pediatr 2008;51:343-50.
9. Lee SI. Prevalence of childhood asthma in Korea: international study of asthma and allergies in childhood. Allergy Asthma Immunol Res 2010;2:61-4.
10. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
11. Seroogy CM, Gern JE. The role of T regulatory cells in asthma. J Allergy Clin Immunol 2005;116:996-9.
12. Curroto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille J. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity 2008;29:114-26.
13. Robinson DS, Larché M, Durham SR. Tregs and allergic disease. J...
14. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, Nam JH, Rhee JH, Hwang KC, Im SH. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A 2010;107:2159-64.

15. Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.

16. Hopfenspirger MT, Agrawal DK. Airway hypersensitivity, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J Immunol 2002;168: 2516-22.

17. Erb KJ, Holloway JW, Sobek A, Moll H, Le Gros G. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guérin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med 1998;187: 561-9.

18. Jason J, Archibald LD, Kwanyanwu OC, Kazembe PN, Chatt JA, Norton E, Dobbie H, Jarvis WR. Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect Immun 2002; 70:6188-95.

19. Li Q, Shen HH. Neonatal bacillus Calmette-Guérin vaccination inhibits de novo allergic inflammatory response in mice via alteration of CD4+CD25+-regulatory cells. Acta Pharmacol Sin 2009;30:125-33.

20. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008;8:193-204.

21. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575-85.

22. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells: their suppressive function. J Immunol 2005;175:7332-40.

23. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.

24. Brinster C, Shevach EM. Bone marrow-derived dendritic cells reverse the anergic state of CD4+CD25+ T cells without reversing their suppressive function. J Immunol 2005;175:7332-40.

25. Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, Cao W, Liu YJ. Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005;436:1181-5.

26. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munh DH, Young JW. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009;114:555-63.

27. Kim YJ, Kim HJ, Kang MJ, Kwun JW, Seo JH, Kim BJ, Yu J, Hong SJ. Effects of Bacillus Calmette-Guérin (BCG) vaccination according to time point of administration on asthma in a murine model. Korean J Asthma Allergy Clin Immunol 2010;30:307-13.

28. Choi MS, Park S, Choi T, Lee G, Haam KK, Hong MC, Min BI, Bae H. Bee venom ameliorates ovalbumin induced allergic asthma via modulating CD4+CD25+ regulatory T cells in mice. Cytokine 2013; 61:256-65.

29. Yu J, Jang SO, Kim BJ, Song YH, Kwun JW, Kang MJ, Choi WA, Jung HD, Hong SJ. The effects of Lactobacillus rhamnosus on the prevention of asthma in a murine model. Allergy Asthma Immunol Res 2010;2:199-205.

30. Tournour KG, Kips JC, Schou C, Pauwels RA. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsive-ness. Clin Exp Allergy 2000;30:79-85.

31. Souahline H, Deghmene AE, Sun J, Mak K, Talal A, Av-Gay Y, Hmama Z. Mycobacterium bovis bacillus Calmette-Guérin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages. J Immunol 2007;179:5137-45.

32. Liu E, Law HK, Lau YL. BCG promotes cord blood monocyte-derived dendritic cell maturation with nuclear Rel-B up-regulation and cytosolic I kappa B alpha and beta degradation. Pediatr Res 2003;54:105-12.

33. Demangel C, Bean AG, Martin E, Feng CG, Kamath AT,Britton WJ. Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guérin-infected dendritic cells. Eur J Immunol 1999;29:1972-9.

34. Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009;182: 111-20.

35. Ahrens B, Gruber C, Rha RD, Freund T, Quarcoc D, Awagyan A, Hutloff A, Dittrich AM, Wahn U, Hamelmell E. BCG priming of dendritic cells enhances T regulatory and Th1 function and suppresses allergen-induced Th2 function in vitro and in vivo. Int Arch Allergy Immunol 2009;150:210-20.

36. Lagrandiere M, Abolhassani M, Vanoirbeek JA, Lima C, Balazac AM, Vargaftig BB, Marchal G. Mycobacterium bovis bacillus Calmette-Guérin killed by extended freeze-drying targets plasmacytoid dendritic cells to regulate lung inflammation. J Immunol 2010;184: 1062-70.

37. Lewkovich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, Diener KM, Sproles AA, Shah JS, Köhl J, Belkaid Y, Wills-Karp M. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 2005;202:1549-61.

38. Lagrandiere MR, Balazac AM, Derlaud E, Leclerc CD, Gerghioiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immn 1996;64:1-9.

39. Fehervari Z, Sakaguchi S. Development and function of CD25+ CD4+ regulatory T cells. Curr Opin Immunol 2004;16:203-8.

40. Xie G, Bai H, Cheng J, Wang S, Xiu N, Yang X. CD8α+ and CD8α- DC subsets from BCG-infected mice inhibit allergic Th2-cell responses by enhancing Th1- and Treg-cell activity respectively. Eur J Immunol 2012;42:165-75.

41. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis 1993;167:1481-97.

42. Christ AP, Rodriguez D, Borotlatto J, Borjucchi E, Keller A, Mucida D, Silva JS, Leite LC, Russo M. Enhancement of Th1 lung immunity induced by recombinant Mycobacterium bovis Bacillus Calmette-Guérin attenuates airway allergic disease. Am J Respir Cell Mol Biol 2010;43:243-52.

43. Barlan I, Bahceciler NN, Akdis M, Akdis CA. Bacillus Calmette-Guérin inhibits airway allergic inflammation in vivo. J Immunol 2003;169:111-20.

44. Fonseca DM, Paula MO, Wowk PF, Campos LW, Gembre AF, Tura D, Marchal G, Arruda LK, Russo M. Enhancement of Th1 lung immunity in mice immunized with Mycobacterium bovis BCG vaccine strains. Infect Immn 1996;64:1-9.

45. Fehérvári Z, Sakaguchi S. Development and function of CD25+ CD4+ regulatory T cells. Curr Opin Immunol 2004;16:203-8.

46. Xie G, Bai H, Cheng J, Fan Y, Wang S, Jiao L, Xiu N, Yang X. CD8α+ and CD8α- DC subsets from BCG-infected mice inhibit allergic Th2-cell responses by enhancing Th1- and Treg-cell activity respectively. Eur J Immunol 2012;42:165-75.